Wild-derived Alzheimer's disease mouse model
By introducing genes such as human amyloid precursor protein, mutated human preseniin 1 and human apolipoprotein in a mouse model, a "humanization" model closer to human Alzheimer's disease was established, and the current situation was solved Some models cannot effectively simulate the pathology of human Alzheimer's disease, achieving more accurate simulation of neurodegeneration and inflammatory responses.
Patent Information
- Application Number
- CN202380034905.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-09
- Filing Date
- 2023-03-09
- Publication Date
- 2024-12-03
AI Technical Summary
The existing Alzheimer's disease mouse model is not sufficient to repeat the extensive neurodegeneration and regional brain atrophy associated with humans, and lacks a full range of clinical and pathological characteristics, which cannot effectively simulate the pathology of human Alzheimer's disease.
A closer approach was established by introducing human amyloid precursor protein (APP), mutated human preseniin 1 (PSEN1), human apolipoprotein (APOE) and human amyloid β and tau in a wild-derived mouse model Models of human genetic diversity for studying the pathogenesis and neuroinflammatory responses of Alzheimer's disease.
The model showed severe neurodegeneration at the early stage, closer to the pathology of human Alzheimer's disease, and was able to more accurately simulate human-related Alzheimer's disease characteristics, such as neurodegeneration, cognitive deficits, and brain increase. Neuroinflammatory provides a more relevant clinical and pathological reenactment platform.
Smart Images

Figure CN119072231A_ABST
Abstract
Description
[0001] Related Applications
[0002] This application claims the benefit of U.S. Provisional Application No. 63 / 318,313, filed on March 9, 2022, under 35 U.S.C. §119(e), the entire contents of which are incorporated herein by reference.
[0003] References to Electronic Sequence Listings
[0004] The contents of the Electronic Sequence Listing (J022770116WO00-SEQ-EAS.xml; size: 4,984 bytes; and creation date: March 9, 2023) are incorporated herein by reference in their entirety. Background Art
[0005] Transgenic mouse models expressing human amyloid precursor protein (APP) and expressing or not expressing human presenilin 1 (PSEN1) have been widely used in vivo Alzheimer's disease (AD) studies to better understand the pathogenesis of Alzheimer's disease. However, such models are generally insufficient to reproduce the extensive neurodegeneration and regional brain atrophy that occur in AD (Drummond et al., Acta Neuropathol. 2017 February; 133 (2): 155-175). In addition, such models have been prepared on limited background strains (such as C57BL6 / J). These transgenic mouse strains have shown a large load of brain parenchymal amyloid deposition, which may be greater than those observed in human patients. Typically, another key marker (neuroinflammation) is limited to a response specific to brain parenchymal plaques. Due to all the reasons mentioned, existing transgenic mouse models expressing APP are limited in their ability to reproduce human-related AD pathology. Summary of the invention
[0006] In some aspects, the present disclosure provides an improved "humanized" mouse model of Alzheimer's disease (AD) in the wild. As known in the art, mice expressing human genes / proteins are generally referred to as "humanized" mice. It should be understood that human genes include human nucleic acid sequences encoding human proteins or human protein domains.
[0007] In some embodiments, the wild-derived humanized mouse AD model expresses human amyloid precursor protein (APP), expresses mutant human presenilin 1 protein (PSEN1, also abbreviated as PSEN1), and expresses (a) human apolipoprotein (APOE) (e.g., human apolipoprotein E4, E3 or E2) or (b) human amyloid β and / or human tau. Modeling AD on a wild-derived background allows for a platform for studying interactions with amyloid on a more human-relevant, genetically diverse background. This background also allows for the exploration of a range of neuroinflammatory responses.
[0008] The humanized mouse model of wild origin provided herein is based at least in part on the following theory: the pathogenesis of AD is studied by regulating the known genetic risk factors in the genetic diversity mouse background to obtain a more clinically relevant model. The theory is tested by introducing the humanized mouse model of wild origin of people's PSEN1 expressing people's APP and mutation into people's risk allele APOE4 and people's amyloid beta and / or people's tau. First, the WSB.AP0E4 mouse model is produced. Then the WSB.APP / PSEN1 model is hybridized with the WSB.APOE4 mouse model to produce a humanized mouse model ("WSB.APP / PSEN1 / APOE4" model) of novel wild origin expressing people's APP, people's PSEN1 and people's APOE4 of mutation. Surprisingly, the humanized AD mouse model of wild origin comprising transgenic amyloid mutation causes neurodegeneration in the cortex and hippocampus of female mice as early as 8 months.
[0009] Therefore, some aspects of the present disclosure provide a wild-derived humanized mouse comprising in its genome a nucleic acid encoding human amyloid precursor protein (APP), a nucleic acid encoding a mutant human presenilin 1 protein (PSEN1), and a nucleic acid encoding human apolipoprotein E.
[0010] In some embodiments, the human apolipoprotein E is human apolipoprotein E4 (APOE4).
[0011] Other aspects of the present disclosure provide a wild-derived humanized mouse comprising in its genome a nucleic acid encoding human amyloid precursor protein (APP), a nucleic acid encoding a mutated human presenilin 1 protein (PSEN1), a nucleic acid encoding human amyloid β, and a nucleic acid encoding human tau.
[0012] In some embodiments, the nucleic acid encoding human APP is a chimeric nucleic acid comprising mouse and human coding sequences.
[0013] In some embodiments, the chimeric nucleic acid comprises a human coding sequence within the A-beta domain of a mouse APP coding sequence.
[0014] In some embodiments, the chimeric nucleic acid encodes human mutations K595N and M596L relative to human APP comprising the amino acid sequence of SEQ ID NO:1.
[0015] In some embodiments, the nucleic acid encoding human APP is an APPswe transgene.
[0016] In some embodiments, the nucleic acid encoding the mutant PSEN1 comprises a human PSEN1 coding sequence comprising a deletion in exon 9.
[0017] In some embodiments, the nucleic acid encoding a mutant PSEN1 is a PSEN1de9 transgene.
[0018] In some embodiments, the mouse comprises a Tg(APPswe,PSEN1de9)85Dbo transgene insertion in its genome.
[0019] In some embodiments, the mouse expresses human APP, human PSEN1, and human apolipoprotein E, optionally human APOE4.
[0020] In some embodiments, the mouse expresses human amyloid beta and human tau.
[0021] In some embodiments, the mouse has a genetic background selected from WSB / EiJ, CAST / EiJ, and PWK / PhJ.
[0022] In some embodiments, the mouse has at least one feature of early-onset Alzheimer's disease, for example, at least one feature of early-onset Alzheimer's disease selected from neurodegeneration, cognitive deficits, and increased neuroinflammation in the brain relative to a control.
[0023] In some embodiments, the mouse is tumor-free or has no measurable tumor burden.
[0024] In some embodiments, the mouse is at least one year old.
[0025] Some aspects of the present disclosure provide a wild-derived humanized WSB mouse comprising an APPswe transgene and a PSENde9 transgene in the genome, and a gene encoding human apolipoprotein E (optionally human apolipoprotein E4 (APOE4)).
[0026] Other aspects of the present disclosure provide a wild-derived humanized mouse comprising in its genome a nucleic acid encoding human apolipoprotein E, optionally human apolipoprotein E4 (APOE4).
[0027] Still further aspects of the present disclosure provide a wild-derived humanized mouse comprising humanized amyloid β and humanized tau in its genome.
[0028] Also provided in other aspects of the present disclosure are cells from the mouse of any of the preceding paragraphs.
[0029] A further aspect of the present disclosure provides a mouse comprising cells having the same genotype as cells from the mouse in any of the preceding paragraphs.
[0030] Some aspects of the present disclosure provide offspring mice of the mouse of any of the preceding paragraphs.
[0031] Some aspects of the present disclosure provide a method comprising producing the mouse of any of the preceding paragraphs. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] Figure 1A and 1B Depicted are immunohistochemistry and corresponding quantification of brain tissues from 8-month-old female mice of WSB, WSB.APOE4, WSB.APP / PSEN1, and WSB.APP / PSEN1 / APOE4 genotypes. Figure 1A Depicted are brain tissue stained with DAPI and antibody NEUN on multiple coronal brain sections spanning the anterior, middle, and posterior regions of the brain. Figure 1B Depicted are the amount of NEUN measured in traced cortical areas averaged across each genotype (upper panel) and a comparison of cortical surface area (lower panel).
[0033] Figure 2 is a graph depicting a comparison of cortical surface area of brain tissue from 4-month-old female mice of WSB, WSB.APOE4, WSB.APP / PSEN1, and WSB.APP / PSEN1 / APOE4 genotypes. DETAILED DESCRIPTION
[0034] Alzheimer's disease (AD) is the most common cause of dementia. Today, AD affects 35 million people, and its global prevalence is expected to reach 115 million by 2050 due to aging populations. AD progresses through three stages: preclinical, mild cognitive impairment (MCI), and dementia. People with MCI have cognitive deficits but no functional impairment, while people with dementia show declines in two or more cognitive domains that gradually progress to the point of functional impairment in work or daily activities. Pathologically, the diagnosis of AD in humans is based on protein aggregates in the brain, including amyloid plaques composed of amyloid-β (AP) peptides and neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau. In humans, the early spatial distribution of plaque pathology, including plaque pathology that first occurs in the hippocampus, is strongly associated with the diagnosis of dementia.
[0035] The mouse model of AD is limited because none of the existing models show the full range of clinical and pathological features of AD, including cognitive and behavioral defects, amyloid plaques, neurofibrillary tangles, gliosis, synaptic loss, axonal lesions, neuronal loss and neurodegeneration. Importantly, different mouse models provide different degrees of AD phenotypes. For example, phenotypes such as cognitive defects and amyloid plaques are observed in almost all AD mouse models, but the human pathology of AD has not yet been repeated. For example, in the B6.APP / PSEN1 mouse model, hippocampus and strong cortical plaque deposition are observed at early time points, which is contrary to the human pathology in which plaques are mainly limited to hippocampus. Different from the B6.APP / PSEN1 mouse model, the mouse model of the present disclosure (which models AD in the context of wild origin) shows severe neurodegeneration, which is more closely similar to human AD pathology.
[0036] In some embodiments, the present disclosure provides a wild-derived humanized mouse model (e.g., a WSB / EiJ mouse model) comprising human amyloid precursor protein (APP), mutated human presenilin 1 protein (PSEN1), and human apolipoprotein E (e.g., human apolipoprotein E4, E3, or E2). In some embodiments, the present disclosure provides a wild-derived humanized mouse model (e.g., a WSB / EiJ mouse model) comprising human APP, mutated human PSEN1, and human amyloid β and / or human tau.
[0037] Parental strains and alleles
[0038] In some embodiments, the mouse model provided herein is produced on a genetic background (such as a WSB background) of wild-type origin. In some embodiments, the mouse model provided herein is produced using the WSB / EiJ strain, such as the WSB.Cg-Tg (APPswe, PSEN1dE9) 85Dbo / How strain (WSB.APP / PS1). WSB.APP / PS1 is a double transgenic mouse expressing chimeric mouse / human amyloid precursor protein (Mo / HuAPP695swe) and mutant human presenilin 1 (PS1-dE9), both of which are directed to CNS neurons. Both mutations are associated with early-onset Alzheimer's disease. The "humanized" Mo / HuAPP695swe transgenic allows mice to secrete human A-β peptides. Both transgenic peptides and whole proteins can be detected by antibodies specific to human sequences in this region (monoclonal 6E10 antibodies from Signet Laboratories). The Swedish mutation (K595N / M596L) included increases the amount of A-β produced by the transgene by being advantageously processed by the β-secretase pathway. Compared with the control, WSB.APP / PS1 female hemizygotes show increased loss of cortical areas and CA1 NEUN+DAPI+ (hippocampus) neurons, as well as impaired short-term memory. Compared with B6.APP / PS1 mice, the number of cortical plaques is less. WSB.APP / PS1 males show reduced hippocampal plaque numbers (compared to B6.APP / PS1 controls), while WSB.APP / PS1 females do not. WSB.APP1 / PS1 mice were produced by backcrossing B6.Cg-Tg (APPswe, PSENldE9) 85Dbo / Mmjax (JAX Stock No.34832-JAX) mice with WSB / EiJ (JAX StockNo.001145) mice for 12 generations.
[0039] In some embodiments, the mouse model provided herein is generated on a genetic background of wild-type origin (e.g., PWK background). In some embodiments, the mouse model provided herein is generated using a PWK / PhJ strain, such as a PWK.Cg-Tg (APPswe, PSEN1dE9) 85Dbo / How strain (PWK.APP / PS1). PWK.APP1 / PS1 mice are generated by backcrossing B6.Cg-Tg (APPswe, PSEN1dE9) 85Dbo / Mmjax (Stock No.34832-JAX) mice with PWK / PhJ (Stock No.003715) mice for 11 generations.
[0040] In some embodiments, the mouse model provided herein is produced on a genetic background (such as CAST background) of wild-type origin. In some embodiments, the mouse model provided herein is produced using CAST / EiJ strain. This strain can be backcrossed with, for example, B6.Cg-Tg (APPswe, PSEN1dE9) 85Dbo / Mmjax (JAX Stock No.34832-JAX) for multiple generations.
[0041] Amyloid Precursor Protein
[0042] Amyloid precursor protein is a single-pass (type I) transmembrane precursor protein that is cleaved into amyloid beta (Aβ), which is the main component of amyloid plaques and is associated with at least one feature of early-onset Alzheimer's disease. Knocking in chimeric mouse / human amyloid precursor protein can lead to secretion of human amyloid-β (Aβ) peptide. In some embodiments, the mouse model comprises a chimeric nucleic acid comprising a human coding sequence in the A-β domain of the mouse APP coding sequence. In some embodiments, the chimeric nucleic acid encodes human Swedish mutations K595N and M596L relative to human APP comprising the amino acid sequence of SEQ ID NO: 1. The included Swedish mutations (K595N and M596L) increase the amount of A-β produced from the transgene by promoting processing through the β-secretase pathway (Shin et al., 2010). In some embodiments, the chimeric nucleic acid is an APPswe transgene encoding a chimeric amyloid beta (A4) precursor protein comprising the Swedish mutations K595N and M596L. See, e.g., Borchelt, David R. et al., Neuron 1996; 17(5): 1005-1013; JAX Stock No. 025970).
[0043] In some embodiments, the human amyloid precursor protein comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the sequence of SEQ ID NO: 1:
[0044] MLPGLALLLLAAWTARALEVPTDGNAGLLAEPQIAMFCGRLNMHMNV
[0045] QNGKWDSDPSGTKTCIDTKEGILQYCQEVYPELQITNVVEANQPVTIQN
[0046] WCKRGRKQCKTHPHFVIPYRCLVGEFVSDALLVPDKCKFLHQERMDV
[0047] CETHLHWHTVAKETCSEKSTNLHDYGMLLPCGIDKFRGVEFVCCPLAE
[0048] ESDNVDSADAEEDDSDVWWGGADTDYADGSEDKVVEVAEEEEVAEV
[0049] EEEEADDDEDDEDGDEVEEEAEEPYEEATERTTSIATTTTTTESVEEV
[0050] VREVCSEQAETGPCRAMISRWYFDVTEGKCAPFFYGGCGGNRNNFDTE
[0051] EYCMAVCGSAMSQSLLKTTQEPLARDPVKLPTTAASTPDAVDKYLETP
[0052] GDENEHAHFQKAKERLEAKHRERMSQVMREWEEAERQAKNLPKADK
[0053] KAVIQHFQEKVESLEQEAANERQQLVETHMARVEAMLNDRRRLALEN
[0054] YITALQAVPPPRRHVFNMLKKYVRAEQKDRQHTLKHFEHVRMVDPKK
[0055] AAQIRSQVMTHLRVIYERMNQSLSLLYNVPAVAEEIQDEVDELLQKEQ
[0056] NYSDDVLANMISEPRISYGNDALMPSLTETKTTVELLPVNGEFSLDDLQ
[0057] PWHSFGADSVPANTENEVEPVDARPAADRGLTTRPGSGLTNIKTEEISE
[0058] VKMDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIATVI
[0059] VITLVMLKKKQYTSIHHGVVEVDAAVTPEERHLSKMQQNGYENPTYK
[0060] FFEQMQN (SEQ ID NO:1).
[0061] Presenilin 1
[0062] Presenilin 1 PSEN1 is a subunit of the gamma-(γ-) secretase complex involved in the cleavage of APP, which produces amyloid-β peptides. Mouse models expressing mutant human presenilin 1 and human APP transgenics are associated with at least one feature of early-onset Alzheimer's disease. In some embodiments, the nucleic acid encoding the mutant PSEN1 comprises a human PSEN1 coding sequence comprising a deletion (DeltaE9) in exon 9. In some embodiments, the nucleic acid is a PSENlde9 transgenic. In some embodiments, the PSENlde9 transgenic is a Tg(APPswe,pSen1de9)85Dbo transgenic insertion. See, for example, Borchelt et al., 1996; JAX Stock No.025970.
[0063] In some embodiments, the human Presenilin 1 protein comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the sequence of SEQ ID NO: 2:
[0064] MTELPAPLSYFQNAQMSEDNHLSNTVRSQNDNRERQEHNDRRSLGHPE
[0065] PLSNGRPQGNSRQVVEQDEEEDEELTLKYGAKHVIMLFVPVTLCMVVV
[0066] VATIKSVSFYTRKDGQLIYTPFTEDTETVGQRALHSILNAAIMISVIVVM
[0067] TILLVVLYKYRCYKVIHAWLIISSLLLLFFFSFIYLGEFFKTYNVAVDYIT
[0068] VALLIWNFGVVGMISIHWKGPLRLQQAYLIMISALMALVFIKYLPEWT
[0069] AWLILAVISVYDLVAVLCPKGPLRMLVETAQERNETLFPALIYSSTMV
[0070] WLVNMAEGDPEAQRRVSKNSKYNAESTERESQDTVAENDDGGFSEEW
[0071] EAQRDSHLGPRSTPESRAAVQELSSSILAGEDPEERGVKLGLGDFIFYS
[0072] VLVGKASATASGDWNTTIACFVAILIGLCLTLLLLAIFKKALPALPISITF
[0073] GLVFYFATDYLVQPFMDQLAFHQFYI(SEQ ID NO:2)
[0074] Apolipoprotein E (APOE)
[0075] The APOE gene provides instructions for making apolipoprotein E. This protein binds to fats (lipids) in the body to form molecules called lipoproteins. Lipoproteins are responsible for packaging cholesterol and other fats and carrying them through the bloodstream. Maintaining normal levels of cholesterol is necessary to prevent conditions that affect the heart and blood vessels (cardiovascular disease), including heart attack and stroke.
[0076] The APOE gene has at least three slightly different forms (alleles). The major alleles are APOE2, APOE3, and APOE4. The most common allele is APOE3, which is found in more than half of the general population. In some embodiments, the nucleic acid encodes human APOE2, APOE3, or APOE4.
[0077] Apolipoprotein E4 (APOE4) is a lipid-binding protein involved in lipoprotein metabolism and is one of the largest known genetic risk factors for late-onset sporadic AD. In some embodiments, the nucleic acid encodes human APOE4.
[0078] In some embodiments, the human APOE4 protein comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the sequence of SEQ ID NO: 3:
[0079] MKVLWAALLVTFLAGCQAKVEQAVETEPEPELRQQTEWQSGQRWEL
[0080] ALGRFWDYLRWVQTLSEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGLVEKVQAAVGTSAAPVPSDNH (SEQ ID NO: 3).
[0081] Amyloid beta
[0082] Amyloid β refers to a peptide of 36-43 amino acids, which is the main component of amyloid plaques found in the brain of people with AD. These peptides are derived from amyloid precursor protein (APP), which is cleaved by β-secretase and γ-secretase in a cholesterol-dependent process and substrate presentation to produce Aβ. In some embodiments, nucleic acid encodes human amyloid β.
[0083] Tau
[0084] Tau refers to a soluble protein isoform produced by alternative splicing from the gene MAPT (microtubule-associated protein Tau) and is associated with neurological pathologies and dementias such as AD. In some embodiments, the nucleic acid encodes human tau.
[0085] Evaluation of neurodegeneration and other symptoms of Alzheimer's disease
[0086] Alzheimer's disease is a brain disorder that slowly destroys memory and thinking skills, and eventually the ability to perform the simplest tasks. In most people with Alzheimer's disease, symptoms first appear later in life. Estimates vary, but experts believe that more than 6 million Americans, most of whom are 65 or older, may have dementia caused by Alzheimer's disease. Alzheimer's disease is currently ranked as the seventh leading cause of death in the United States and is the most common cause of dementia among older adults.
[0087] Dementia is the loss of cognitive function (thinking, memory, and reasoning) and behavioral abilities to the point where it interferes with a person's daily life and activities. Dementia ranges in severity from the mildest stage, when it just starts to affect a person's function, to the most severe stage, when a person must become completely dependent on others for help with basic activities of daily living. The causes of dementia can vary, depending on the type of brain changes that may have occurred. Other dementias include dementia with Lewy bodies, frontotemporal disorder, and vascular dementia. People often have mixed dementia - a combination of two or more types of dementia. For example, some people have Alzheimer's disease and vascular dementia.
[0088] As used herein, characteristics of early-onset Alzheimer's disease include, but are not limited to, neurodegeneration, vascular defects, mitochondrial dysfunction, cognitive deficits, amyloid plaque deposition, cortical plaque deposition, and neuroinflammation in the brain.
[0089] In some embodiments, the wild-derived humanized mouse model of the present invention comprises in its genome a nucleic acid encoding human amyloid precursor protein (APP), a nucleic acid encoding a mutant human presenilin 1 protein (PSEN1), and a nucleic acid encoding human apolipoprotein E (e.g., human apolipoprotein E4, E3, or E2) (e.g., WSB.APP / PSEN1 / APOE4 mouse and / or WSB.APOE4). Surprisingly, the mouse has at least 20%, at least 30%, or at least 40% higher, or about 20-40% higher neurodegeneration relative to a control mouse of the same age (e.g., a WSB mouse, such as a WSB.APP / PSEN1 mouse or a C57BL6 / J mouse) (see Figure 1A-1B and Figure 2 ). As used herein, neurodegeneration refers to the reduction or depletion of neurons. Neurodegeneration can be measured using immunofluorescence staining of NEUN (a surrogate of neurons) in mouse brain regions. Immunofluorescence staining methods well known in the art are contemplated herein. NEUN positive staining indicating neurons may be present in coronal brain sections within the anterior, middle, and posterior regions of the brain of the mouse brain of the present disclosure. The total immunofluorescence staining of neurodegeneration in a wild-source mouse brain region can be compared with the total immunofluorescence staining in different regions of the same wild-source mouse brain. The total immunofluorescence staining of neurodegeneration in the mouse brain can also be compared with the total immunofluorescence staining of neurodegeneration in the control mouse brain.
[0090] In some embodiments, in the humanized mouse model of wild origin of the present disclosure, the neurodegeneration in the brain region can be increased by at least 5%, at least 10%, at least 20%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65% or at least 70% relative to the neurodegeneration in the brain region of the control mouse of the same age. In some embodiments, spot counting immunohistochemistry can be used to assess neurodegeneration. In some embodiments, in the humanized mouse model of wild origin, the neurodegeneration in the brain region can be increased by at least 20% relative to the neurodegeneration in the brain region of the control mouse of the same age. In some embodiments, in the humanized mouse model of wild origin, the neurodegeneration in the brain region can be increased by about 20% relative to the neurodegeneration in the brain region of the control mouse of the same age. In other embodiments, neurodegeneration can be assessed based on surface area. In some embodiments, in a wild-derived humanized mouse model, neurodegeneration in a brain region can be increased by at least 35% or at least 40% relative to neurodegeneration in a brain region of a control mouse of the same age. In some embodiments, in a wild-derived humanized mouse model, neurodegeneration in a brain region can be increased by about 35% or about 40% relative to neurodegeneration in a brain region of a control mouse of the same age.
[0091] In some embodiments, the wild-derived humanized mouse model disclosed herein has greater vascular defects relative to control mice of the same age (e.g., WSB mice, such as WSB.APP / PSEN1 mice or C57BL6 / J mice). As used herein, vascular defects refer to any reduction in vascular function known to be associated with AD. Vascular defects can be measured using immunofluorescence staining of known vascular markers. Immunofluorescence staining methods well known in the art are contemplated herein. The total immunofluorescence staining of vascular defects in regions of the humanized mouse brain of wild origin can be compared with the total immunofluorescence staining in different regions of the humanized mouse brain of the same wild origin. The total immunofluorescence staining of vascular defects in the mouse brain can also be compared with the total immunofluorescence staining of vascular defects in the control mouse brain.
[0092] In some embodiments, in the wild-derived humanized mouse model of the present disclosure, vascular defects in a brain region can be increased by at least 5%, at least 10%, at least 20%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% relative to vascular defects in a brain region of a control mouse of the same age.
[0093] In some embodiments, the wild-derived humanized mouse model disclosed herein has higher mitochondrial dysfunction relative to control mice of the same age (e.g., WSB mice, such as WSB.APP / PSEN1 mice or C57BL6 / J mice). As used herein, mitochondrial dysfunction refers to any reduction in mitochondrial function known to be associated with AD. Mitochondrial dysfunction can be measured using immunofluorescence staining of known mitochondrial markers. Immunofluorescence staining methods well known in the art are contemplated herein. The total immunofluorescence staining of mitochondrial dysfunction in the region of the humanized mouse brain of wild origin can be compared with the total immunofluorescence staining in different regions of the humanized mouse brain of the same wild origin. The total immunofluorescence staining of mitochondrial dysfunction in the mouse brain can also be compared with the total immunofluorescence staining of mitochondrial dysfunction in the control mouse brain.
[0094] In some embodiments, in a wild-derived humanized mouse model, mitochondrial dysfunction in a brain region can be increased by at least 5%, at least 10%, at least 20%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% relative to mitochondrial dysfunction in a brain region of a control mouse of the same age.
[0095] In some embodiments, the wild-derived humanized mouse model of the present invention has greater cognitive deficits relative to control mice of the same age (e.g., WSB mice, such as WSB.APP / PSEN1 mice or C57BL6 / J mice). As used herein, cognitive deficits are used to describe impairments in different cognitive domains and can be used interchangeably with the term cognitive impairment. Cognitive deficits in mice of the present invention can be measured according to, but not limited to, any of the following behavioral assays: Y-maze measurements of working and short-term memory, orifice boards, open fields, and touch screens.
[0096] The Y-type maze is used to assess the short-term memory of mice. Spontaneous alternation (a measure of spatial working memory) can be assessed by allowing mice to explore all three arms of the maze, and is driven by the innate curiosity of rodents to explore previously unvisited areas. Mice with complete working memory and therefore complete prefrontal cortex function will remember the arms previously visited and show a trend of entering non-recently visited arms. Spatial reference memory emphasized by hippocampus can also be tested by placing test mice in a Y-type maze that closes one arm during training. The test is based on the spontaneous tendency of mice to spend more time exploring new arms rather than familiar arms. In some embodiments, when compared with control mice, the humanized mouse model of wild origin of the present disclosure can spend more equal or less time to explore new arms relative to familiar objects.
[0097] The hole board task is used to measure the exploratory behavior, motor activity and cognitive function of mice. The test is based on the innate curiosity and attraction of mice to novelty. The hole board consists of a small square stage with a removable platform as a floor, which has a group of equally spaced circular holes on the surface. Mice spontaneously approach the holes and explore them by briefly inserting their noses into them, and this behavior is defined as nose touch (or head dip). If after a period of time, the mice are re-exposed to the hole board, the novelty of the hole is reduced. Animals with complete long-term memory will show a reduced frequency of nose touches in the holes. In some embodiments, the humanized mouse model of wild origin disclosed in the present invention may have increased nose touch events relative to control mice, and control mice avoid nose touches to the holes previously explored by the mice.
[0098] The open field task is a simple sensorimotor test used to determine the general activity level, total motor activity, and exploratory habits in rodent models of CNS disorders. The assessment is performed in a square white Plexiglas box. The animal is placed in a stage and allowed to move freely for 10 minutes while being recorded by an overhead camera. The following parameters of the continuous footage are then analyzed by an automatic tracking system: the distance moved, speed, and time spent in a predefined area. In some embodiments, the wild-derived humanized mouse model of the present disclosure can show different levels of activity level, total motor activity, and exploratory habits relative to control mice.
[0099] The touch screen task is a method for performing simple and complex cognitive neuroscience measurements in mice. The touch screen task uses an automated touch screen platform, where a significant diversity of cognitive functions can be tested in mice. In some embodiments, the wild-derived humanized mouse model of the present disclosure can exhibit lower cognitive function relative to control mice.
[0100] In some embodiments, the humanized mouse model of wild origin of the present disclosure has increased amyloid plaque deposition in the hippocampus of the brain relative to the cortical area of the brain. As used herein, amyloid plaque deposition refers to A-β protein deposition, which gradually accumulates and forms plaque-like lesions throughout the life of the mouse. Amyloid plaque deposition can be measured using immunofluorescence staining of amyloid precursor protein in the cortex and / or hippocampus of the mouse brain. Immunofluorescence staining methods well known in the art are contemplated herein. Positive staining of amyloid precursor protein indicating amyloid plaque deposition may be present in the cortex or hippocampus of the mouse brain of the present disclosure, or in both the cortex and hippocampus. The total immunofluorescence staining of amyloid plaque deposition in the cortical region can be compared with the total immunofluorescence staining in the hippocampus of the same mouse. The total immunofluorescence staining of amyloid plaque deposition in the mouse brain can also be compared with the total immunofluorescence staining of amyloid plaque deposition in the control mouse brain.
[0101] In some embodiments, in the wild-derived humanized mouse model of the present disclosure, amyloid plaque deposition in the hippocampal region can be increased by at least 5%, at least 10%, at least 20%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 100% relative to amyloid plaque deposition in the cortical region.
[0102] In some embodiments, the wild-derived humanized mouse model of the present invention has more cortical plaque deposition relative to the cortical plaque deposition of control mice (e.g., WSB mice, such as WSB.APP / PSEN1 mice or C57BL6 / J mice) of the same age. As used herein, cortical plaque deposition refers to plaque deposition in the cerebral cortex region. Cortical plaque deposition can be measured using immunofluorescence staining of amyloid precursor protein in the mouse cerebral cortex region. Immunofluorescence staining methods well known in the art are contemplated herein. Positive staining of amyloid precursor protein indicating cortical plaque deposition may be present in the cortical region of the mouse brain of the present invention. The total immunofluorescence staining of cortical plaque deposition in the mouse brain is compared relative to the total immunofluorescence staining of cortical plaque deposition in the control mouse brain.
[0103] In some embodiments, the wild-derived humanized mouse model of the present disclosure has higher cerebral amyloid angiopathy relative to cerebral amyloid angiopathy of control mice (e.g., WSB mice, such as WSB.APP / PSEN1 mice or C57BL6 / J mice) of the same age. As used herein, cerebral amyloid angiopathy refers to amyloid β-peptide deposition in small to medium-sized blood vessels of the brain and pia mater.
[0104] In some embodiments, in the wild-derived humanized mouse model of the present disclosure, cortical plaque deposition and / or cerebral amyloid angiopathy can be increased by at least 5%, at least 10%, at least 20%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% relative to cortical plaque deposition in control mice of the same age (e.g., WSB mice, such as WSB.APP / PSEN1 mice or C57BL6 / J mice).
[0105] In some embodiments, the plaque region specificity of the wild-derived humanized mouse model disclosed herein is different from that of control mice of the same age (e.g., WSB mice, such as WSB.APP / PSEN1 mice or C57BL6 / J mice). As used herein, plaque region specificity refers to the mouse brain region (e.g., cortical or hippocampal region, or both cortical and hippocampal regions) where amyloid plaque deposition may occur. In humans, plaque pathology first occurs in the hippocampus (i.e., plaque region specificity in humans first occurs in the hippocampal region). The wild-derived humanized mouse model exhibits plaque region specificity in both the cortical and hippocampal regions of the mouse brain.
[0106] In some embodiments, the neuroinflammation of the wild-derived humanized mouse model of the present disclosure is changed relative to control mice of the same age (e.g., WSB mice, such as WSB.APP / PSEN1 mice or C57BL6 / J mice). As used herein, neuroinflammation is indicated by positive immunofluorescence staining of microglia activation and astrocyte reactivity in the brain. Microglia activation can be measured by staining brain tissue with microglia markers. Astrocyte reactivity can be measured by staining brain tissue with astrocyte markers. The total immunofluorescence staining of microglia activation and / or astrocyte reactivity in the mouse brain can be compared with the total immunofluorescence staining of microglia activation and / or astrocyte reactivity in the control mouse brain.
[0107] In some embodiments, the neuroinflammation of the wild-derived humanized mouse model of the present invention (e.g., indicated by immunofluorescence staining of astrocyte reactivity or microglia activation) is higher relative to control mice of the same age (e.g., WSB mice, such as WSB.APP / PSEN1 mice or C57BL6 / J mice). In some embodiments, the neuroinflammation of the wild-derived humanized mouse model of the present invention (e.g., indicated by immunofluorescence staining of astrocyte reactivity) is higher relative to control mice of the same age (e.g., WSB mice, such as WSB.APP / PSEN1 mice or C57BL6 / J mice) can be at least 20%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 100%.
[0108] In some embodiments, the wild-derived humanized mouse model of the present disclosure does not have a tumor. In some embodiments, the wild-derived humanized mouse model of the present disclosure does not have a measurable tumor burden. As used herein, "measurable tumor burden" refers to any non-zero tumor volume value. Any mechanism known in the art for calculating tumor volume is contemplated herein.
[0109] How to use
[0110] The mouse models provided herein (e.g., humanized mouse models of wild origin) can be used for many applications. In some embodiments, the humanized mouse models of wild origin disclosed herein respond to human APOE (e.g., APOE4, APOE3, or APOE2) or human amyloid β and / or human tau in the brain to show neurodegeneration. Therefore, the humanized mouse models of wild origin disclosed herein can be used to further evaluate the effects of human APOE (e.g., human APOE4) or human amyloid β and / or human tau in genetically more diverse mouse models.
[0111] In some embodiments, the wild-derived humanized mouse model of the present disclosure can be used to test how a specific agent (e.g., therapeutic agent) or medical procedure (e.g., cell or tissue transplantation) affects the effect of human APOE (e.g., APOE4, APOE3, or APOE2) or human amyloid β and / or human tau as AD risk factors. In some embodiments, a specific agent (e.g., therapeutic agent) can be delivered to a wild-derived humanized mouse model of the present disclosure, and the changes in neurodegeneration caused by the agent can be measured relative to a wild-derived humanized mouse model of the present disclosure that has not received the agent as described above. Changes in neurodegeneration as a result of treatment with an agent can be indicated by an increase or decrease in NEUN staining in a brain region as described above.
[0112] Non-limiting examples of pharmaceutical agents include therapeutic agents, such as anti-cancer agents and anti-inflammatory agents, and prophylactic agents, such as vaccines.
[0113] In some embodiments, the wild-derived humanized mouse model of the present invention can be subjected to a medical procedure (e.g., cell or tissue transplantation), and the changes in neurodegeneration caused by the medical procedure can be measured relative to the wild-derived humanized mouse model of the present invention that has not been subjected to the medical procedure as described above. Changes in neurodegeneration as a result of a medical procedure (e.g., cell or tissue transplantation) can be indicated by an increase or decrease in NEUN staining in a brain region as described above.
[0114] Non-limiting examples of medical procedures include transplantation of cells (eg, microglia) from other mouse background strains or from human sources.
[0115] In some embodiments, the wild-derived humanized mouse model disclosed herein (e.g., WSB.APP / PSEN1 / APOE4 mouse model) can be used to evaluate the effects of agents or medical procedures on neurodegeneration in response to human APOE (e.g., APOE4, APOE3, or APOE2) or human amyloid β and / or human tau. Therefore, provided herein are methods comprising administering an agent or medical procedure to a mouse model and evaluating the effects of an agent or medical procedure on neurodegeneration in response to human APOE (e.g., APOE4, APOE3, or APOE2) or human amyloid β and / or human tau in mice.
[0116] Evaluating the effect of an agent or medical procedure on neurodegeneration in response to human APOE (e.g., APOE4, APOE3, or APOE2) or human amyloid β and / or human tau in a wild-type humanized mouse model of the present disclosure (e.g., a WSB.APP / PSEN1 / APOE4 mouse model) includes, for example, comparing the results of the evaluation to an appropriate control, such as, but not limited to, the effect of the compound on a control mouse (e.g., a WSB mouse, such as a WSB.APP / PSEN1 mouse or a C57BL6 / J mouse).
[0117] Mouse Model
[0118] Herein, for simplicity, reference is made to "mouse" and "mouse models" (e.g., surrogates of human conditions). It should be understood that these terms are used interchangeably throughout the specification to encompass "rodents" and "rodent models," including mice, rats, and other rodent species, unless otherwise indicated.
[0119] It should also be understood that the standard genetic nomenclature used herein provides unique identification for different rodent strains, and the strain symbol conveys basic information about the type of the strain or original species used and the genetic content of the strain. The International Committee on Standardized Genetic Nomenclature of Mouse has promulgated rules for symbolizing strains and original species. These rules can be obtained online from the Mouse Genome Database (MGD; informatics.jax.org), and published in printed copies (Lyon etc., 1996). The strain symbol generally includes a laboratory registration code (laboratory code). The registration is kept in the Institute for Laboratory Animal Research (ILAR) of the National Academy of Sciences in Washington, DC. The laboratory code can be obtained electronically on the website of ILAR (nationalacademies.org / ilar / institute-for-laboratory-animal-research). See also Davisson MT, Genetic and Phenotypic Definition of Laboratory Mice and Rats / What Constitutes an Acceptable Genetic-Phenotypic Definition, National Research Council (US) International Committee of the Institute for Laboratory Animal Research. Washington (DC): National Academies Press (US); 1999.
[0120] The mouse model provided herein is a transgenic mouse model expressing human amyloid precursor protein (APP) and human presenilin 1 protein (PSEN1). In some embodiments, the transgenic mouse model expresses human apolipoprotein E4 (APOE4). In some embodiments, the transgenic mouse model expresses human amyloid protein β. In some embodiments, the transgenic mouse model expresses human tau. Transgenic mice are mice with exogenous nucleic acids (e.g., transgenic) (integrated into their genome) in their genome. Methods for producing transgenic mice are well known.
[0121] Three conventional methods for generating transgenic mice include DNA microinjection (Gordon and Ruddle, Science 1981: 214: 1244-124, incorporated herein by reference), embryonic stem cell-mediated gene transfer (Gossler et al., Proc. Natl. Acad. Sci. 1986, 83: 9065-9069, incorporated herein by reference), and retrovirus-mediated gene transfer (Jaenisch, Proc. Natl. Acad. Sci. 1976, 73: 1260-1264, incorporated herein by reference), any of which can be used as provided herein. Genome editing methods using, for example, clustered regularly interspaced palindromic repeats (CRISPR / Cas) nucleases, transcription activator-like effector nucleases (TALENs), or zinc finger nucleases (ZFNs) are described elsewhere herein.
[0122] After delivering the nucleic acid to a fertilized embryo (e.g., a one-cell embryo (e.g., a zygote) or a multicellular embryo (e.g., a developmental stage after the zygote, such as a blastocyst), the fertilized embryo is transferred to a pseudopregnant female, which then produces offspring. The presence or absence of nucleic acid encoding human FcRn and / or chimeric IgG antibodies can be confirmed, for example, using a variety of genotyping methods (e.g., sequencing and / or genomic PCR).
[0123] As described in the examples herein, new mouse models can also be created by breeding parental lines. Utilizing various available sudden changes, knockouts, knock-ins, transgenics, Cre-lox, Tet induction systems and other mouse strains, multiple sudden changes and transgenics can be combined to produce new mouse models. Multiple mouse strains can be bred together to produce double, triple or even quadruple and more multiple mutant / transgenic mice.
[0124] In some embodiments, the parental mouse is bred to produce F1 mouse. The parental mouse can be, for example, homozygous, heterozygous, hemizygous or homozygous ineffective at a specific allele. Homozygous describes the genotype of two identical alleles at a given locus, heterozygous describes the genotype of two different alleles at the locus, hemizygous describes the genotype that is only composed of a single copy of a specific gene in other diploid organisms, and homozygous ineffective refers to other diploid organisms in which two copies of a gene are missing.
[0125] In some embodiments of the present disclosure, one or more cells can be isolated from the mice described in the present disclosure. In some embodiments, one or more cells isolated from the mice of the present disclosure contain the same genotype as the cells from the mice.
[0126] In some embodiments, WSB.APOE4 mice are generated by backcrossing APOE4 to the WSB background for multiple generations (e.g., 5 generations). Methods comprising breeding offspring mice are also contemplated.
[0127] In some embodiments, WSB.APP / PSEN1 / APOE4 mice are produced by backcrossing APOE4 to a WSB background for multiple generations (e.g., 5 generations). The offspring WSB.APOE4 mice are then hybridized with homologous WSB.APP / PSEN1 mice. The offspring offspring are hybridized to allow the generation of WSB.APP / PSEN1 / AP0E4 genotypes. Methods including breeding offspring mice are also contemplated.
[0128] Humanized mouse models from wild-type sources
[0129] In some embodiments, humanized mouse models of wild origin are provided herein. As known in the art, mice of wild origin have a genetically heterogeneous background. Introducing transgenic mutations on the genetic diversity background of wild-derived mice may be more representative of humans, and human pathology can be reenacted in a more relevant manner. Non-limiting examples of humanized mouse models of wild origin include the following mouse strains: WSB / EiJ, CAST / EiJ, and PWK / PhJ. Humanized mouse models of other wild origins are also contemplated herein.
[0130] In some embodiments, the humanized mouse of wild origin has WSB / EiJ genotype (e.g., JacksonLabs Stock No.: #001145). Watkins Star Line B (WSB) is a wild mouse captured from the Eastern Shore of Maryland. The mouse of wild origin is genetically different from common laboratory mice in many complex phenotypic characteristics, and is a valuable tool for genetic mapping, evolution and systematic studies. Humanized mouse strains of other wild origins are considered herein.
[0131] In some embodiments, the wild-derived humanized mouse has a PWK / PhJ genotype (eg, JacksonLabs Stock No.: #003715).
[0132] In some embodiments, the wild-derived humanized mouse has a CAST / EiJ genotype (eg, JacksonLabs Stock No.: #000928).
[0133] Nucleic Acids: Engineering and Delivery
[0134] The mouse model described herein comprises a nucleic acid encoding human APP, and in some embodiments, comprises a nucleic acid encoding a mutated human PSEN1. In some embodiments, the mouse model described herein further comprises a mouse App allele and / or a mouse Psen1 allele. In some embodiments, the mouse model comprises a human APP transgenic and a mutated human PSEN1 transgenic. In some embodiments, a transgenic (such as a human APP transgenic and / or a mutated human PSEN1 transgenic) is integrated into the mouse genome. Human APP and mutated human PSEN1 transgenics (JAX Stock No.025970) are described and incorporated herein by reference. In some embodiments, the mouse model comprises human apolipoprotein E (e.g., human APOE4, APOE3 or APOE2). In some embodiments, the mouse model comprises human amyloid β and human tau.
[0135] In some embodiments, the nucleic acid provided herein is engineered. Engineered nucleic acid is a nucleic acid that does not exist in nature (e.g., at least two nucleotides are covalently linked together, and in some cases, contain a phosphodiester bond, referred to as a phosphodiester backbone). Engineered nucleic acid includes recombinant nucleic acid and synthetic nucleic acid. Recombinant nucleic acid is a molecule constructed by joining nucleic acids (e.g., isolated nucleic acid, synthetic nucleic acid, or a combination thereof) from two different organisms (e.g., humans and mice). Synthetic nucleic acid is a molecule amplified or synthesized by chemical or other means. Synthetic nucleic acid includes those nucleic acids that are chemically modified or otherwise modified but can be paired (combined) with naturally occurring nucleic acid molecules. Recombinant and synthetic nucleic acids also include those molecules produced by any of the aforementioned replications.
[0136] The engineered nucleic acid can comprise DNA (e.g., genomic DNA, cDNA, or a combination of genomic DNA and cDNA), RNA, or a hybrid molecule, for example, wherein the nucleic acid contains any combination of deoxyribonucleotides and ribonucleotides (e.g., artificial or natural), and any combination of two or more bases, including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine, hypoxanthine, isocytosine, and isoguanine.
[0137] In some embodiments, the nucleic acid is complementary DNA (cDNA).cDNA is synthesized from a single-stranded RNA (eg, messenger RNA (mRNA) or micro RNA (miRNA)) template in a reaction catalyzed by reverse transcriptase.
[0138] The engineered nucleic acids disclosed herein can be produced using standard molecular biology methods (see, e.g., Green and Sambrook, Molecular Cloning, A Laboratory Manual, 2012, Cold Spring Harbor Press). In some embodiments, GIBSON is used. Cloning produces nucleic acids (see, e.g., Gibson, DG et al., Nature Methods, 343-345, 2009; and Gibson, DG et al., Nature Methods, 901-903, 2010, each of which is incorporated herein by reference). Three enzyme activities are usually used in a single tube reaction: 5' exonuclease, 3' extension activity of DNA polymerase and DNA ligase activity. The 5' exonuclease activity cuts off the 5' end sequence and exposes the complementary sequence for annealing. The polymerase activity then fills the gap on the annealing domain. The DNA ligase then seals the nick and covalently links the DNA fragments together. The overlapping sequences of adjacent fragments are much longer than those used in Golden Gate Assembly, thus resulting in a higher percentage of correct assembly. Other methods for producing engineered nucleic acids can be used according to the present disclosure.
[0139] Gene is different nucleotide sequences, and its order determines the order of monomers in polynucleotides or polypeptides.Gene usually encodes protein.Gene can be endogenous (naturally present in host organism) or exogenous (naturally or by genetic engineering transfer to host organism).Allele is produced by mutation and one of two or more alternative forms of gene found at the same locus on chromosome.In some embodiments, gene includes promoter sequence, coding region (such as exon), non-coding region (such as intron) and regulatory region (also referred to as regulatory sequence).
[0140] Mice containing human genes are considered to contain human transgenes. Transgenes are genes that are exogenous to the host organism. In other words, transgenes are genes that have been transferred to the host organism naturally or by genetic engineering. Transgenes do not naturally occur in the host organism (organism containing the transgene, such as mice).
[0141] A promoter is a nucleotide sequence (e.g., ATG) to which RNA polymerase binds to initiate transcription. A promoter is typically located directly upstream of the transcription start site (at the 5' end). In some embodiments, a promoter is an endogenous promoter. An endogenous promoter is a promoter that occurs naturally in the host animal.
[0142] An open reading frame is a stretch of consecutive codons that begins with a start codon (e.g., ATG) and ends with a stop codon (e.g., TAA, TAG, or TGA) and encodes a polypeptide, such as a protein. An open reading frame is operably linked to a promoter if the promoter regulates the transcription of the open reading frame.
[0143] Exons are regions of genes that code for amino acids. Introns (and other noncoding DNA) are regions of genes that do not code for amino acids.
[0144] In some embodiments, the nucleotide sequence of the encoding product (e.g., protein) has a length of 200 base pairs (bp) to 100 kilobases (kb). In some embodiments, the nucleotide sequence has a length of at least 10kb. For example, the nucleotide sequence can have a length of at least 15kb, at least 20kb, at least 25kb, at least 30kb, or at least 35kb. In some embodiments, the nucleotide sequence has a length of 10 to 100kb, 10 to 75kb, 10 to 50kb, 10 to 30kb, 20 to 100kb, 20 to 75kb, 20 to 50kb, 20 to 30kb, 30 to 100kb, 30 to 75kb, or 30 to 50kb.
[0145] Any nucleic acid provided herein can have a length of 200bp to 500kb, 200bp to 250kb or 200bp to 100kb. In some embodiments, the nucleic acid has a length of at least 10kb. For example, the nucleic acid can have a length of at least 15kb, at least 20kb, at least 25kb, at least 30kb, at least 35kb, at least 50kb, at least 100kb, at least 200kb, at least 300kb, at least 400kb or at least 500kb. In some embodiments, the nucleic acid has a length of 10 to 500kb, 20 to 400kb, 10 to 300kb, 10 to 200kb or 10 to 100kb. In some embodiments, the nucleic acid has a length of 10 to 100 kb, 10 to 75 kb, 10 to 50 kb, 10 to 30 kb, 20 to 100 kb, 20 to 75 kb, 20 to 50 kb, 20 to 30 kb, 30 to 100 kb, 30 to 75 kb, or 30 to 50 kb. The nucleic acid can be circular or linear.
[0146] In some embodiments, nucleic acid as described herein includes modification. Modification of nucleic acid is any operation on nucleic acid relative to corresponding wild-type nucleic acid (e.g., naturally occurring nucleic acid). Therefore, genomic modification is any operation on nucleic acid in genome (e.g., coding region, non-coding region and / or regulatory region) relative to corresponding wild-type nucleic acid in genome (e.g., naturally occurring (unmodified) nucleic acid). Non-limiting examples of nucleic acid (e.g., genome) modification include deletion, insertion, "indel" (deletion and insertion) and substitution (e.g., point mutation). In some embodiments, deletion, insertion, indel or other modification in gene leads to frameshift mutation, so that gene no longer encodes functional product (e.g., protein). Modification also includes chemical modification, such as chemical modification of at least one nucleobase. Methods of nucleic acid modification, such as those leading to gene inactivation, are known, and include but are not limited to RNA interference, chemical modification and gene editing (e.g., using recombinase or other programmable nuclease systems, such as CRISPR / Cas, TALEN and / or ZFN).
[0147] As known in the art, loss-of-function mutations result in gene products with little or no function. Null mutations are a type of loss-of-function mutation that results in a gene product without function. In some embodiments, the inactivated allele is a null allele. Other examples of loss-of-function mutations include missense mutations and frameshift mutations.
[0148] Nucleic acid can be modified, such as one or more alleles of a gene, so that it does not produce a functional gene product (e.g., a functional protein) of a detectable level. Therefore, an inactivated allele is an allele that does not produce a functional gene product (e.g., a functional protein) of a detectable level. The detectable level of protein is any protein level detected using a standard protein detection assay (e.g., flow cytometry and / or ELISA). In some embodiments, the allele of inactivation is not transcribed. In some embodiments, the inactivated allele does not encode a functional protein.
[0149] Carriers for delivering nucleic acids include minicircles, plasmids, bacterial artificial chromosomes (BACs), and yeast artificial chromosomes. However, it should be appreciated that carriers may not be needed. For example, circularized or linearized nucleic acids can be delivered to embryos without their carrier backbones. The carrier backbone is small (~4kb), and the donor DNA to be circularized can be in the range of, for example, >100bp to 50kb.
[0150] Methods for delivering nucleic acids to mouse embryos to generate transgenic mice include, but are not limited to, electroporation (see, e.g., Wang W et al., J Genet Genomics 2016; 43(5):319-27; WO 2016 / 054032; and WO 2017 / 124086, each of which is incorporated herein by reference), DNA microinjection (see, e.g., Gordon and Ruddle, Science 1981:214:1244-124, incorporated herein by reference), embryonic stem cell-mediated gene transfer (see, e.g., Gossler et al., Proc. Natl. Acad. Sci. 1986;83:9065-9069, incorporated herein by reference), and retrovirus-mediated gene transfer (see, e.g., Jaenisch, Proc. Natl. Acad. Sci. 1976;73:1260-1264, incorporated herein by reference), any of which can be used as provided herein.
[0151] Example
[0152] Example 1: Generation of the WSB.APP / PSEN1 / APOE4 Mouse Model
[0153] WSB.APP / PSEN1 / APOE4 was generated by first backcrossing APOE4 to the WSB background for 5 generations. The offspring WSB.APOE4 mice were then crossed with congenic WSB.APP / PSEN1 mice. The offspring progeny were crossed to allow for WT, APOE4, and APOE4.APP / PSEN1 genotypes.
[0154] Immunohistochemistry
[0155] WSB, WSB.APOE4, WSB.APP / PSEN1 and WSB.APP / PSEN1 / APOE4 female mice were 8 months old, sacrificed and brain tissue was collected for immunohistochemistry. Brain tissue was stained with DAPI and antibody NEUN on multiple coronal brain sections within the anterior, middle and posterior regions of the brain. The stained sections were then scanned with a Versa slide scanner and the images were converted for use in the IMARIS software. The cortical and hippocampal regions were tracked and the amount of NEUN corresponding to DAPI was then assessed. The surface area was also measured in each tracked area. Representative images of 8-month-old female WSB of all genotypes in the hindbrain region are shown in Figure 1A middle. Figure 1BThe upper graph shown in depicts the amount of NEUN measured in the traced cortical area averaged in each genotype. Relative to WT WSB, WSB.APOE4 has significantly less NEUN, which is a proxy for neurons. Relative to WSB.APP / PSEN1, WSB.APOE4.APP / PSEN1 also has significantly less NEUN. Figure 1B The bottom graph shown in the is a comparison of surface area. Cortical surface area is lower in WSB.APOE4.APP / PSEN1 when compared to WSB.APP / PSEN1 and WSB.APOE4. Overall, this suggests that the addition of APOE4 to the WSB background is an important contributor to neurodegeneration, even in the absence of amyloid drivers such as APP / PSEN1.
[0156] Data from 4-month-old mice as described above showed that WSB.APOE4 females had significantly more neurons than WSB, and WSB.APP / PSEN1 / APOE4 had significantly more neurons than WSB.APP / PSEN1 in the mesocortical region ( Figure 2 ). This mouse data correlates with human data showing that APOE4 carriers have more synapses earlier in life due to less pruning during development. None of these findings were present in the B6 background when APOE4 was present.
[0157] All references, patents, and patent applications disclosed herein are hereby incorporated by reference with respect to the subject matter for which they are individually cited, which in some cases may be incorporated in their entirety.
[0158] Unless explicitly stated to the contrary, the indefinite articles "a" and "an" as used herein in the specification and claims should be understood to mean "at least one".
[0159] It should also be understood that in any method claimed herein that includes more than one step or action, the order of the steps or actions of the method is not necessarily limited to the order in which the steps or actions of the method are described unless explicitly stated to the contrary.
[0160] In the claims and the foregoing specification, all transitional phrases such as "comprising," "including," "carrying," "having," "containing," "involving," "holding," "including," etc. shall be understood as open-ended, i.e., meaning including but not limited to. Only the transitional phrases "consisting of" and "consisting essentially of" shall be closed or semi-closed transitional phrases, respectively, as set forth in Section 2111.03 of the U.S. Patent Office Manual of Patent Examining Procedures.
[0161] The terms "about" and "substantially" preceding a numerical value mean ±10% of the stated numerical value.
[0162] Where a range of values is provided, every value between the upper and lower end of that range is specifically contemplated and described herein.
Claims
1. A wild-derived humanized mouse, comprising in its genome a nucleic acid encoding human amyloid precursor protein (APP), a nucleic acid encoding a mutant human presenilin 1 protein (PSEN1), and a nucleic acid encoding human apolipoprotein E. 2 . The wild-derived humanized mouse according to claim 1 , wherein the human apolipoprotein E is human apolipoprotein E4 (APOE4).
3. A wild-derived humanized mouse, comprising in its genome a nucleic acid encoding human amyloid precursor protein (APP), a nucleic acid encoding a mutated human presenilin 1 protein (PSEN1), a nucleic acid encoding human amyloid β, and a nucleic acid encoding human tau.
4. A wild-derived humanized mouse according to any one of the preceding claims, wherein the nucleic acid encoding human APP is a chimeric nucleic acid comprising a mouse coding sequence and a human coding sequence.
5. The wild-derived humanized mouse of claim 4, wherein the chimeric nucleic acid comprises a human coding sequence in the A-β domain of the mouse APP coding sequence.
6. The wild-derived humanized mouse of claim 4 or 5, wherein the chimeric nucleic acid encodes human mutations K595N and M596L relative to human APP comprising the amino acid sequence of SEQ ID NO:
1.
7. The wild-derived humanized mouse of claim 6, wherein the nucleic acid encoding human APP is an APPswe transgene. 8 . The wild-derived humanized mouse of any one of the preceding claims, wherein the nucleic acid encoding the mutant PSEN1 comprises a human PSEN1 coding sequence comprising a deletion in exon 9. 9 . The wild-derived humanized mouse of claim 8 , wherein the nucleic acid encoding the mutated PSEN1 is a PSEN1de9 transgene.
10. The wild-derived humanized mouse of claim 9, wherein the mouse comprises a Tg(APPswe, PSEN1de9)85Dbo transgenic insertion in its genome.
11. The wild-derived humanized mouse according to any one of claims 1, 2 and 4-10, wherein the mouse expresses the human APP, the human PSEN1 and the human apolipoprotein E, optionally human APOE4.
12. The wild-derived humanized mouse according to any one of claims 3 to 10, wherein the mouse expresses the human amyloid β and the human tau.
13. A wild-derived humanized mouse according to any one of the preceding claims, wherein the mouse has a genetic background selected from WSB / EiJ, CAST / EiJ and PWK / PhJ.
14. A wild-derived humanized mouse according to any one of the preceding claims, wherein the mouse has at least one feature of early-onset Alzheimer's disease.
15. The wild-derived humanized mouse of claim 14, wherein the at least one characteristic of early-onset Alzheimer's disease is selected from the group consisting of neurodegeneration, cognitive deficits, and increased neuroinflammation in the brain relative to a control.
16. The wild-derived humanized mouse of any preceding claim, wherein the mouse is tumor-free or has no measurable tumor burden.
17. The wild-derived humanized mouse according to any one of the preceding claims, wherein the mouse is at least one year old.
18. A wild-derived humanized WSB mouse comprising an APPswe transgene and a PSENde9 transgene in its genome, and a gene encoding human apolipoprotein E, optionally human apolipoprotein E4 (APOE4).
19. A wild-derived humanized mouse comprising in its genome a nucleic acid encoding human apolipoprotein E, optionally human apolipoprotein E4 (APOE4).
20. A wild-derived humanized mouse comprising humanized amyloid β and humanized tau in its genome.
21. A cell from the mouse of any preceding claim.
22. A mouse comprising cells having the same genotype as cells from the mouse of any one of the preceding claims.
23. Offspring mice of the mouse according to any one of the preceding claims.
24. A method comprising producing a mouse according to any one of the preceding claims.
Citation Information
Patent Citations
High efficiency, high throughput generation of genetically modified mammals by electroporation
WO2016054032A1
Genetically modified non-human mammals by multi-cycle electroporation of CAS9 protein
WO2017124086A1
Alzheimer's disease animal model and use thereof
CN111936628A
Expression cassette and vector comprising alzheimer's disease-related mutant genes and cell line transformed by means of same
US20170112109A1
Human genomic construct reporter cells and mouse models to screen therapeutics against microglia-expressed disease associated genes
WO2020154348A1
Cited By
Construction method of Alzheimer's disease mouse model
CN120077989A
